The use of chemogenetic approaches to study the physiological roles of muscarinic acetylcholine receptors in the central nervous system

被引:12
|
作者
Bradley, Sophie J. [1 ]
Tobin, Andrew B. [1 ]
Prihandoko, Rudi [1 ]
机构
[1] Univ Glasgow, Coll Med Vet & Life Sci, Inst Mol Cell & Syst Biol, Ctr Translat Pharmacol, Glasgow G12 8QQ, Lanark, Scotland
基金
英国医学研究理事会; 英国生物技术与生命科学研究理事会;
关键词
Chemical genetics; Muscarinic receptors; Designer receptors activated by designer drugs; Receptors activated solely by synthetic ligands; Central nervous system; PROTEIN-COUPLED RECEPTORS; PARVALBUMIN-POSITIVE INTERNEURONS; DESIGNED G(I)-COUPLED RECEPTOR; BETA-CELL FUNCTION; CLOZAPINE-N-OXIDE; ALLOSTERIC MODULATION; DRUG DEVELOPMENT; TRANSGENIC MICE; ACTIVATION; LIGAND;
D O I
10.1016/j.neuropharm.2017.11.043
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Chemical genetic has played an important role in linking specific G protein-coupled receptor (GPCR) signalling to cellular processes involved in central nervous system (CNS) functions. Key to this approach has been the modification of receptor properties such that receptors no longer respond to endogenous ligands but rather can be activated selectively by synthetic ligands. Such modified receptors have been called Receptors Activated Solely by Synthetic Ligands (RASSLs) or Designer Receptors Exclusively Activated by Designer Drugs (DREADDs). Unlike knock-out animal models which allow detection of phenotypic changes caused by loss of receptor functions, RASSL and DREADD receptors offer the possibility of rescuing "knock-out" phenotypic deficits by administration of the synthetic ligands. Here we describe the use of these modified receptors in defining the physiological role of GPCRs and validation of receptors as drug targets. This article is part of the Special Issue entitled 'Neuropharmacology on Muscarinic Receptors'. (C) 2017 Published by Elsevier Ltd.
引用
收藏
页码:421 / 426
页数:6
相关论文
共 50 条